Glyconia

Company Overview

Snapshot

Founded in June 2022 by Vered Padler-Karavani, Glyconia operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing breakthrough CAR-T immunotherapy.

Business overview

Glyconia is a Health Tech & Life Sciences company specializing in immunotherapy solutions. The company has developed a unique platform and multidisciplinary know-how for identifying and specifically targeting cancer cells based on their unique sugar-coating, which differs from healthy cells. Glyconia's proprietary technology aims to target cancer cell-surface glycosylation with high efficiency and potency, leading the development of breakthrough CAR-T immunotherapy. The company operates in the Pharmaceuticals sector, serving the broader Healthcare & Life Sciences market.

Company Intelligence Q&A

What is Glyconia's primary focus?

Glyconia is focused on developing breakthrough CAR-T immunotherapy solutions that target the unique sugar-coating on cancer cells, differentiating them from healthy cells.

When was Glyconia founded?

Glyconia was founded in June 2022.

Who is a key founder of Glyconia?

Vered Padler-Karavani is a founder, President, and CTO of Glyconia.

What is Glyconia's current operational status?

Glyconia ceased to operate in January 2024.

What market does Glyconia primarily serve?

Glyconia primarily serves the Healthcare & Life Sciences market, with a focus on Pharmaceuticals.